July 20, 2006
Burlington, Ontario
THE JENEX CORPORATION (“Jenex” or the “Corporation”) (TSX Venture Exchange – JEN). The Corporation is pleased to announce the launch of Therapik® in the Peoples Republic of China and Europe. An agreement has been reached with EuroDev BV, through Competitive Technologies, Inc. (Amex: CTT), to market Therapik® in China and Europe. EuroDev BV with offices in the Netherlands, France and China, specializes in European and Asian business development. Jenex has received their first purchase order for Therapik® to be distributed in the Peoples Republic of China as a result of this arrangement.
“This opening order for Therapik® establishes Jenex’s entry into world markets and favourably positions the Corporation for expansion in these regions with our other products”, states Don Felice, Vice President. “This is a significant milestone for Jenex as we continue to pursue our corporate goal of establishing international markets for products developed from our Thermal Defence Technology.”
Additionally, Therapik® is being test-marketed in approximately 800 high profile retail stores in Europe. The Corporation expects this distribution will increase to several thousand retail locations throughout Europe upon the conclusion of a successful market test.
Michael Jenkins, President and CEO states, “The relationship with EuroDev BV, facilitated by CTT, enables us to aggressively pursue mass market opportunities in Europe and China through EuroDev’s vast networks in these regions. We are very optimistic about the potential for Therapik® in these markets and expect the Therapik® brand to make a significant financial contribution to the Corporation.“
Jenex continues to pursue marketing opportunities for Therapik® and interceptCS™ in several international markets and plans to add new markets for both products over the next year.
About The Jenex Corporation
The Jenex Corporation owns a patented Thermal Therapy technology. The first device developed from this technology is the Therapik® product, for relief of pain and itch caused by insect stings and bites. Therapik® has been approved as a Class II medical device in Canada and the United States, and has received CE approval in Europe. The second device, interceptCS™ is the first product clinically proven to prevent cold sores. interceptCS™ was launched exclusively in Canada with Shoppers Drug Mart/Pharmaprix, in April of this year. More information about the Corporation can be found at www.jenexcorp.com & www.interceptCS.com .
Enquiries:
Michael A. Jenkins, President
The Jenex Corporation
940 Sheldon Court, Suite 207
Burlington, Ontario
L7L 5K6
Telephone: (905) 632-3830
Facsimile: (905) 632-3774
Email: jenex@jenexcorp.com
The TSX Venture Exchange has not reviewed and does not accept responsibility for the accuracy or the contents of this press release. Certain information included in this press release is forward-looking and is subject to important risks and uncertainties. The results or events predicted in these statements may differ materially from actual results or events.
